Framework Agreement for the approval of the supply of original biological and biosimilar medicines based on the active principles adalimumab, trastuzumab, etanercept, rituximab, infliximab and bevacizumab.

Adalimumab 20 mg, solution for injection in syringe and / or pre-filled pen.

Bevacizumab 25 mg / ml, concentrate for solution for infusion (4 ml vial).

Bevacizumab 25 mg / ml, concentrate for solution for infusion (16 ml vial).

Adalimumab 40 mg, solution for injection in syringe and pre-filled pen.

Trastuzumab 150 mg, powder for concentrate for solution for infusion.

Trastuzumab 420 mg, powder for concentrate for solution for infusion.

Etanercept 25 mg, solution for injection in a syringe and / or pre-filled pen.

Etanercept 50 mg, solution for injection in syringe and pre-filled pen.

Rituximab 100 mg, concentrate for solution for infusion.

Rituximab 500 mg, concentrate for solution for infusion.

Infliximab 100 mg, powder for concentrate for solution for infusion.